Abstract
Active and passive immunization to prevent Influenza virus and Human Immunodeficiency Virus1 (HIV-1) infection has long been considered a potential treatment modality. Earlier efforts were largely unsuccessful as the antibodies studied neutralized only a narrow spectrum of viral strains. However, recent discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and influenza strains has laid the foundation for such immunization strategies with universal vaccines being the ultimate aim. These antibodies target multiple different epitopes on the HIV envelope and influenza glycoprotein, thus neutralizing a broad range of viral variants. In this review, the role of broadly neutralizing antibodies (bNAb) in HIV and Influenza infection will be discussed along with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
